Technology Platform


News Center

Gmax Announces Approval of Glutazumab for Investigational New Drug (IND) in China

Glutazumab (GMA102) has been approved by Center for Drug Evaluation (CDE, CFDA) for the IND of type 2 diabetes (T2D).

Gmax to Present at the PHA’s 2018 International PH Conference and Scientific Sessions

June 28, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the preclinical and the phase 1 clinical trial results of its ETa antibody Getagozumab ...